Tenor Capital Management adds Anacor Pharmaceuticals Inc (ANAC) to its portfolio

Anacor Pharmaceuticals Inc (ANAC) : Tenor Capital Management added new position in Anacor Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 5,000 shares of Anacor Pharmaceuticals Inc which is valued at $320,150 , the company said in a statement filed on May 13, 2016 with the SEC.Anacor Pharmaceuticals Inc makes up approximately 12.55% of Tenor Capital Management’s portfolio.

Other Hedge Funds, Including , Wellington Management Group Llp reduced its stake in ANAC by selling 326,184 shares or 15.55% in the most recent quarter. The Hedge Fund company now holds 1,771,058 shares of ANAC which is valued at $113.4 Million. Anacor Pharmaceuticals Inc makes up approx 0.03% of Wellington Management Group Llp’s portfolio. Hap Trading added ANAC to its portfolio by purchasing 24,018 company shares during the most recent quarter which is valued at $1.5 Million. Anacor Pharmaceuticals Inc makes up approx 0.18% of Hap Trading’s portfolio.Ifp Advisors Inc reduced its stake in ANAC by selling 51 shares or 4.9% in the most recent quarter. The Hedge Fund company now holds 990 shares of ANAC which is valued at $58,113.

Anacor Pharmaceuticals Inc closed down -0.19 points or -0.19% at $99.24 with 57,19,833 shares getting traded on Wednesday. Post opening the session at $99.56, the shares hit an intraday low of $99.21 and an intraday high of $99.6 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Anacor Pharmaceuticals Inc reported $-0.36 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on May 10, 2016. Analyst had a consensus of $-0.35. The company had revenue of $17.54 million for the quarter, compared to analysts expectations of $18.66 million. The company’s revenue was up 14.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.30 EPS.

Many Wall Street Analysts have commented on Anacor Pharmaceuticals Inc. Mizuho Downgraded Anacor Pharmaceuticals Inc on May 18, 2016 to ” Neutral”, Price Target of the shares are set at $99.25.Shares were Reiterated by Wedbush on May 3, 2016 to “Outperform” and Lowered the Price Target to $ 148 from a previous price target of $152 .Mizuho Initiated Anacor Pharmaceuticals Inc on Mar 11, 2016 to “Buy”, Price Target of the shares are set at $103.

Anacor Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on discovering developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Company’s lead product candidate AN2728 is an investigational non-steroidal topical PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis and psoriasis. The Company’s product KERYDIN (tavaborole) topical solution is an oxaborole antifungal. The Company also has a pipeline of other internally discovered topical and systemic boron-based compounds in early stages of research and development which include AN3365. The Company’s compound AN5568 (SCYX-7158) is licensed to Drugs for Neglected Diseases initiative (DNDi) for the potential treatment of human African trypanosomiasis (sleeping sickness).

Leave a Reply

Anacor Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Anacor Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.